References

- 1. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki, WN, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001;71:1189-204.
- Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 2002;20:2118-26.
 Chang G, Orav EJ, Tong M-Y, Antin JH. Predictors of 1-year
- Chang G, Orav EJ, Tong M-Y, Antin JH. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics 2004;45:378-85.
 Sherman AC, Simonton S, Latif U, Spohn R, Tricot G.
- Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplantation 2004;33: 955-62.
- Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers MED, Martin PJ. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 2004;291:2335-43.
- Hoffman LH, Szkrumelak N, Sullivan AK. Psychiatric assessment of candidates for bone marrow transplantation: a psychodynamically-oriented approach. Int J Psychiatry Med 1999; 29:13-28.
- Eid KAB, Miranda ECM, Vigorito AC, Aranha, FJP, Oliveira GB, De Souza, CA. The availability of full match sibling donor and feasibility of allogeneic bone marrow transplantation in Brazil. Braz J Biol Res 2003;36:315-21.
- 8. Olbrisch ME, Levenson JL, Hamer R. The PACT: a rating scale for the study of clinical decision-making in psychosocial screening criteria for organ transplant candidates. Clin Transpl 1989;3:164-9.
- Twillman RK, Manetto C, Wellisch DK, Wolcott DL. The Transplant Evaluation Rating Scale. A revision of the psychosocial levels system for evaluating organ transplant candidates. Psychosomatics 1993;34:144-5.
- Mori DL, Gallagher P, Milne J. The Structured Interview for Renal Transplantation--SIRT. Psychosomatics 2000;41:393-406.

Epidemiology

No relationship between hepatitis C infection and risk of myeloid malignancy

The etiology of myeloid malignancies is related to chromosomal damage caused by irradiation, alkylating agents, viral infection and so forth;' however, few clinical studies have been published on the association between viral infection and the development of myeloid malignancies.

haematologica 2005; 90:572-574 (http://www.haematologica.org/journal/2005/4/572.html)

Hepatitis C virus (HCV) is the major pathogen of posttransfusion and sporadic non-A, non-B chronic hepatitis, and one of the most important causes of chronic liver disease.² It involves many organs, causing extrahepatic manifestations.² Crovatto *et al.* demonstrated that peripheral blood neutrophils are the replication sites of HCV,³ while it remains unknown whether the infection occurs at the level of the stem cells or subsequently during myeloid cell differentiation. A few clinical studies suggest a weak, non-significant association between acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and antibody to HCV;⁴⁵ however, it remains unknown whether HCV infection might contribute to the development of myeloid malignancies. We conducted a hospital-

| 572 | haematologica/the hematology journal | 2005; 90(4)

based case-control study to evaluate this association.

We selected 94 patients with myeloid malignancies from 326 consecutively registered patients with hematologic malignancies at Toranomon Hospital between 1995 and 2001. Myeloid malignancies were classified according to the International Classification of Diseases 10th version (ICD-10). Myeloid leukemia (C92), monocytic leukemia (C-93), acute erythroleukemia (C94.0), megakaryocytic leukemia (C94.2) and myelodysplastic syndrome (D46) were included in this study. All the patients had newly diagnosed myeloid malignancies, and had never received any chemotherapy. Controls were selected randomly from hospitalized orthopedics patients (n=188) and otolaryngology patients (n=188), each group matched for age, sex and year of visit with a 1:2 case-control ratio. We excluded patients with a history of malignancy. Age was further adjusted as a continuous variable in conditional logistic regression analysis. The following data were extracted from medical records; age, sex, smoking habit, alcohol use, hepatitis B virus surface (HBs) antigen, anti-HCV antibody (anti-HCV-Ab), anti-human T-cell leukemia virus (HTLV)-1 antibody, anti-HIV antibody, and a history of malignancy. The definition of HCV infection was positive anti-HCV-Ab by enzyme immunoassay (EIA-I or EIA-II, Ortho Diagnostic Systems, Tokyo, Japan) on admission. To minimize unknown biases, we used two independent control groups in which each case was matched to four individuals for age, sex, and year of admission.

All statistical analyses were performed with STATA, version 7. (STATA Corp., College Station, TX, USA). Bivariate analyses were performed with χ^2 , Fisher's exact, or Wilcoxon's signed-rank test. Attribution of HCV infection was evaluated in terms of odds ratios (OR) and 95% confidence intervals (CI). A conditional logistic regression model was applied to estimate ORs and 95% CIs. The study protocol was approved by the institutional review board.

The patients' characteristics are shown in Table 1. Five patients with myeloid malignancies had HCV infection. The prevalence of HCV infection in cases (5.3%) was comparable with that in orthopedic (6.4%), otolaryngology (6.9%) and combined controls (6.6%) (Table 1). Age-adjusted odds ratios for seropositivity of HCV are shown in Table 2. There was no significant association between seropositivity of HCV and development of myeloid malignancies.

Our study does not support an association between HCV infection and development of myeloid malignancies. These findings are comparable with those of previous reports.⁴⁵ While further evaluation of the association is necessary, currently available observations, including ours, suggest that HCV infection is unlikely to increase the rate of myeloid malignancies. This contrasts with the association between HCV infection and lymphoid malignancies.¹ Although the development of both myeloid and lymphoid malignancies is considered to be affected by genotoxic factors such as viral infections, irradiation, and chemotherapeutic agents, our observation suggests that the mechanisms of tumorigenesis are different between lymphoid and myeloid malignancies.

A case-control study is suitable for studying a rare disease such as myeloid malignancies; however, this study has several problems to be discussed. First, it was hospital-based, and possibly affected by an unrecognized bias in the case and the control groups. Secondly, data on

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Table 1. Patients' characteristics and clinical outco	omes of patients infe	cted with hepatitis C	virus.	
Male:Female 23:71 46:142 46:142 84:284 Age range (median) 45:89 (64) 43:90 (63) 44:89 (62) 43:90 (63) Number of patients by age groups 40:49 22 26 48 60:59 25 56 55 111 60:69 37 69 77 146 70:79 14 31 24 55 80: 5 10 6 16 Clinical diagnosis of case group (D:10 codes Meloid leukemia 22 57 Acute myeloid leukemia (32.2 57 7 146 15 Clinical diagnosis of case group (D:10 codes Meloid leukemia 232.1 13 Acute myeloid nocytic leukemia (32.2 5 5 5 5 Malee Clinical diagnosit case group (D:10 codes 13 24 4 Acute myeloid nocytic leukemia (32.4 4 4 4 Acute enythoneocytic leukemia (33.1 3 3 <th>F N</th> <th>Case Group; Patients with Myeloid Aalignancies (n=94)</th> <th>Control Group 1; Orthopedic Group (n=188)</th> <th>Control Group 2; Otolaryngology Group (n=188)</th> <th>Total Controls (n=376)</th>	F N	Case Group; Patients with Myeloid Aalignancies (n=94)	Control Group 1; Orthopedic Group (n=188)	Control Group 2; Otolaryngology Group (n=188)	Total Controls (n=376)
Age range (median) 45.89 (64) 43.90 (63) 44.89 (62) 43.90 (63) Number of patients by age groups	Male:Female	23:71	46:142	46:142	84:284
45-89 (64) 43-90 (63) 44-89 (62) 43-90 (63) Number of patients by age groups 40-49 12 22 26 48 40-49 12 22 26 48 50-59 111 60-69 37 69 77 146 55 50 10 6 16 Clinical diagnosis of case group ICD-10 codes 10 6 16 16 Clinical diagnosis of case group ICD-10 codes 10 6 16 16 Clinical diagnosis of case group ICD-10 codes 13 24 55 10 6 16 Clinical diagnosis of case group ICD-10 codes 13 24 55 10 6 16 Clinical diagnosis of case group ICD-10 codes 13 24 5 16	Age range (median)				
Number of patients by age groups 40.49 12 22 26 48 50-59 25 56 55 111 60-69 37 69 77 146 70-79 14 31 24 55 80- 5 10 6 16 Clinical diagnosis of case group (CD-10 codes		45-89 (64)	43-90 (63)	44-89 (62)	43-90 (63)
40.49 12 22 26 48 50-59 25 56 55 111 60-69 37 69 77 146 70-79 14 31 24 55 80- 5 10 6 16 Clinical diagnosis of case group ICD-10 codes Myeloid leukemia C92 57 Acuter myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acuter myelomocyclic leukemia C92.4 4 Acuter myelomocyclic leukemia C92.9 9 Monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified C93.1 3 Other leukemia C94.0 1 Acute mythroleukemia C94.2 2 Myeloidylastic syndrome D46 29 Refractory anemia with sideroblasts, so stated D46.1 1 Refractory anemia with excess of blasts D46.2 10 Atuet erythroleukemia D46.3 4	Number of patients by age groups				
50-59 25 56 55 11 60-69 37 69 77 146 70-79 14 31 24 55 80- 5 10 6 16 Clinical diagnosis of case group (CD-10 codes Myeloid leukemia C92 57 Acute myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acute promyelocytic leukemia C92.5 5 Myeloid leukemia C93.0 2 Acute monocytic leukemia C93.0 2 Acute monocytic leukemia C93.0 2 Acute monocytic leukemia C93.0 2 Chronic myeloid cleukemia C93.0 2 Chronic monocytic leukemia C94.0 1 Acute enythroleukemia C94.0 1 Acute monocytic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia with sideroblasts, so stated D46.1 1 Refractory anemia with excess of blasts D46.3 4	40-49	12	22	26	48
00-00 70-79 12 70-79 14 31 24 24 55 55 80- 5 10 6 16 Clinical diagnosis of case group ICD-10 codes Myeloid leukemia C92 57 Acute myeloid leukemia 57 Acute myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acute myeloid leukemia C92.5 5 Myeloid leukemia C92.5 5 5 Myeloid leukemia C93.0 2 Acute myelonocytic leukemia C93.0 2 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute myelohastic leukemia C93.0 2 Chronic monocytic leukemia C93.0 2 2 1 3 1 Other leukemias of specified cell type C94.0 1 3 2 1 1 Acute megakaryoblastic leukemia C94.0 1 4 4 4 4 4 Myelodysplastic syndrome D46.0 4 4 4 4 4 6 4 6 4 6	50-59	25	56	55	111
00-03 70-79 14 31 24 35 31 24 35 24 35 80- 5 10 6 16 Clinical diagnosis of case group ICD-10 codes	60-69	23	60	33 77	1/6
North B0-1451245380-510616Clinical diagnosis of case groupICD-10 codesICD-10 codesMyeloid leukemiaC92.026Chronic myeloid leukemiaC92.113Acute propulocytic leukemiaC92.44Acute myelocytic leukemiaC92.55Myeloid leukemiaC93.02Chronic monocytic leukemiaC93.13Other leukemiaC93.13Other leukemiaC94.01Acute engakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia with sideroblastsD46.11Refractory anemia with excess of blastsD46.34Others1010Anti-HCV-antibody121325Negative87174173347Nesing2224	70.70	1/	21	24	55
OU- 5 10 6 10 Clinical diagnosis of case group ICD-10 codes	10-19	14 E	10	24	10
Clinical diagnosis of case group ICD-10 codes Myeloid leukemia C92 57 Acute myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acute myelomonocytic leukemia C92.4 4 Acute myelomonocytic leukemia C92.5 5 Myeloid leukemia C93.0 2 Monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.2 2 Myelodysplastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia with sideroblasts, so stated D46.1 1 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with sideroblasts D46.3 4 Refractory anemia with excess of blasts D46.3 4 Others 10 174 173 347 Myeloidyei S*1 12 13 25 <td>80-</td> <td>C</td> <td>10</td> <td>0</td> <td>10</td>	80-	C	10	0	10
Myeloid leukemia C92 57 Acute myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acute myelomonocytic leukemia C92.5 5 Myeloid leukemia C93.0 2 Monocytic leukemia C93.0 2 Monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute myeloidlatic leukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia with sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.3 4 Others 10 10 Anti-HCV-antibody 10 173 Positive 5*1 12 13 Negative 87 174 173 Negative 87 174 173	Clinical diagnosis of case group	ICD-10 codes			
Acute myeloid leukemia C92.0 26 Chronic myeloid leukemia C92.1 13 Acute promyelocytic leukemia C92.5 5 Myeloid leukemia, unspecified C93.0 2 Monocytic leukemia C93.0 2 Acute myelonocytic leukemia C93.0 2 Acute monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94.0 3 Acute megakaryoblastic leukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic cyndrome D46 29 Refractory anemia with sideroblasts, so stated D46.0 4 Refractory anemia with excess of blasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Anti-HCV-antibody	Myeloid leukemia	C92	57		
Chronic myeloid leukemiaC92.113Acute promyelocytic leukemiaC92.44Acute myelomonocytic leukemiaC92.55Myeloid leukemia, unspecifiedC92.99Monocytic leukemiaC93.02Chronic monocytic leukemiaC93.02Chronic monocytic leukemiaC93.13Other leukemia of specified cell typeC943Acute megakaryoblastic leukemiaC94.01Acute megakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia with excess of blastsD46.11Refractory anemia with excess of blasts with transformationD46.34Others101Anti-HCV-antibody121325Negative87174173347Missing2224	Acute myeloid leukemia	C92.0	26		
Acute promyelocytic leukemia C92.4 4 Acute myelomonocytic leukemia C92.5 5 Myeloid leukemia, unspecified C93.0 2 Monocytic leukemia C93.0 2 Acute monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.2 10 Anti-HCV-antibody 1 13 25 Negative S*1 12 13 25 Negative 87 174 173 347	Chronic myeloid leukemia	C92.1	13		
Acute myelomonocytic leukemiaC92.55Myeloid leukemia, unspecifiedC92.99Monocytic leukemiaC93.02Acute monocytic leukemiaC93.02Chronic monocytic leukemiaC93.13Other leukemias of specified cell typeC943Acute megakaryoblastic leukemiaC94.01Acute megakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia without sideroblastsD46.11Refractory anemia with excess of blastsD46.210Refractory anemia with excess of blastsD46.210Anti-HCV-antibody1011PositiveS*11213Negative87174173Negative224	Acute promyelocytic leukemia	C92.4	4		
Nation of position of position of positionCositionCositionMyeloid leukemia, unspecifiedC92.99Monocytic leukemiaC93.02Chronic monocytic leukemiaC93.13Other leukemias of specified cell typeC943Acute erythroleukemiaC94.01Acute megakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia with sideroblastsD46.11Refractory anemia with sideroblastsD46.11Refractory anemia with excess of blastsD46.210Refractory anemia with excess of blastsD46.34Others101Anti-HCV-antibody121325Negative87174173347Nissing224	Acute myelomonocytic leukemia	092.5	5		
Myolou leukemia C93 5 Acute monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with sideroblasts D46.2 10 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 Anti-HCV-antibody 7 Positive 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Myeloid leukemia unspecified	C02.0	ğ		
Monocytic leukemiaC935Acute monocytic leukemiaC93.02Chronic monocytic leukemiaC93.13Other leukemias of specified cell typeC943Acute erythroleukemiaC94.01Acute megakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia without sideroblasts, so statedD46.11Refractory anemia with sideroblastsD46.11Refractory anemia with excess of blastsD46.210Refractory anemia with excess of blasts with transformationD46.34Others1010Anti-HCV-antibody121325Negative87174173347Nissing2224		032.3	3		
Acute monocytic leukemia C93.0 2 Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 13 25 Anti-HCV-antibody 87 174 173 347 Wissing 2 2 2 4	Monocytic leukemia	C93	5		
Chronic monocytic leukemia C93.1 3 Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 10 Anti-HCV-antibody 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Acute monocytic leukemia	C93.0	2		
Other leukemias of specified cell type C94 3 Acute erythroleukemia C94.0 1 Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 10 Anti-HCV-antibody 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Chronic monocytic leukemia	C93.1	3		
Acute erythroleukemiaC94.01Acute megakaryoblastic leukemiaC94.22Myelodysplastic syndromeD4629Refractory anemia without sideroblasts, so statedD46.04Refractory anemia with sideroblastsD46.11Refractory anemia with excess of blastsD46.210Refractory anemia with excess of blasts with transformationD46.34Others1010Anti-HCV-antibody5*1121325Negative87174173347Missing2224	Other leukemias of specified cell type	C94	3		
Acute megakaryoblastic leukemia C94.2 2 Myelodysplastic syndrome D46 29 Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 Anti-HCV-antibody 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 2 4	Acute ervthroleukemia	C94 0	1		
Myelodysplastic syndromeD4629Refractory anemia without sideroblasts, so statedD46.04Refractory anemia with sideroblastsD46.11Refractory anemia with excess of blastsD46.210Refractory anemia with excess of blasts with transformationD46.34Others10Anti-HCV-antibodyPositiveSitive5*1121325Negative87174173347Wissing2224	Acute megakaryoblastic leukemia	C94.2	2		
Refractory anemia without sideroblasts, so stated D46.0 4 Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts D46.3 4 Others 10 Anti-HCV-antibody 10 Positive 5*1 12 Negative 87 174 Wissing 2 2	Myelodysplastic syndrome	D46	29		
Refractory anemia with sideroblasts D46.1 1 Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 Anti-HCV-antibody Positive 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 2 4	Refractory anemia without sideroblasts so stated	D46.0	4		
Refractory anemia with excess of blasts D46.2 10 Refractory anemia with excess of blasts with transformation D46.3 4 Others 10 Anti-HCV-antibody Positive 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Refractory anemia with sideroblasts	D46 1	1		
Anti-HCV-antibody 5*1 12 13 25 Negative 87 174 173 347	Petractory anomia with excess of blasts	D/16.2	10		
Anti-HCV-antibody 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Defractory anomia with excess of blacts with transformation	D40.2	10		
Anti-HCV-antibody 10 Positive 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 4	Relidcioly diletilid with excess of bidsts with tidlisioniduon	D40.5	4		
Anti-HCV-antibody 5*1 12 13 25 Positive 87 174 173 347 Missing 2 2 2 4	oulers		10		
Positive 5*1 12 13 25 Negative 87 174 173 347 Missing 2 2 2 2 4	Anti-HCV-antibody				
Negative 87 174 173 347 Missing 2 2 2 4	Positive	5*1	12	13	25
Missing 2 2 2 A	Negative	87	174	173	347
	Missing	2	2	2	4

*1: The myeloid malignancies were myelodysplastic syndrome (n=2) and acute myeloid leukemia (n=3).

 Table 2. Age-adjusted odds ratios for seropositity of HCV using a conditional logistic regression model.

	Controls				
	Combined	Orthopedic	Otolaryngology		
Total*1	0.83	0.85	0.90		
	(0.31-2.24, 0.72)	(0.29-2.48, 0.82)	(0.24-3.39, 0.82)		
Myeloid leukemia*2	1.41	1.40	1.80		
_	(0.36-5.56, 0.63)	(0.31-6.38, 0.90)	(0.27-11.9, 0.96)		
Myelodysplastic	0.86	1.04	0.36		
syndrome	(0.18-4.04, 0.85)	(0.19-5.73, 0.96)	(0.02-5.43, 0.46)		
Chronic myeloid leukemia*3 0		0	0		

**: each column denotes the age-adjusted, 95% confidence interval and p value.
 **: this represents C92-94 (ICD-10) excluding C92.1. **: none of the 13 patients with chronic myeloid leukemia was positive for anti-HCV-Ab.

HCV-RNA levels were not collected in this study, and it is not apparent how many of the patients were still replicating the virus. Lastly, the small number of HCV-positive patients among cases limits the interpretation of the study. The results of this study are non-confirmatory regarding an association between HCV infection and the development of myeloproliferative diseases. We are now planning a large-sized, multicenter hospital-based study. A community-based study is also warranted to investigate the association among the general population.

> Naoko Murashige,* Masahiro Kami,*° Hiroshi Iwata,° Yukiko Kishi,* Keitaro Matsuo#

*Hematopoietic Stem-cell Transplantation Unit, the National Cancer Center Hospital, Tokyo, Japan; ^oDepartment of Hematology, Toranomon Hospital, Tokyo, Japan; *Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan Key words: acute myeloid leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, hospital-based case control study

Correspondence: Masahiro Kami, M.D., Hematopoietic Stem Cell Transplant Unit, the National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Phone: international +81.3.35422511. Fax: international +81.3.35423815. E-mail: mkami@ncc.go.jp

References

- 1. Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol 1997;24:3-16.
- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
- 3. Crovatto M, Pozzato G, Zorat F, Pussini E, Nascimben F, Baracetti S, et al. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus. Haematologica 2000;85:356-61.
- Gentile G, Mele A, Monarco B, Vitale A, Pulsoni A, Visani G, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. The Italian Leukemia Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:227-30.
- Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian multicenter case-control study. Italian Multi-Center case-control study. Haematologica 2004;89:70-6.